What is a Paraneoplastic (Neoplastic) Syndrome?
Paraneoplastic syndromes are remote effects of cancer caused by autoimmune or hormonal mechanisms—not by the tumor itself, its metastases, infection, ischemia, or metabolic disruptions—that can affect any organ system and often present before the cancer is clinically apparent. 1
Core Definition and Mechanisms
Paraneoplastic syndromes occur when cancer triggers systemic effects through two primary pathways 1:
- Hormonally-based: Ectopic production of hormones, functionally active peptides, enzymes, or cytokines by tumor cells
- Immunologically-based: Autoantibodies produced during anti-cancer defense that cross-react with normal tissues, causing autoimmune damage to organs distant from the tumor
The key distinguishing feature is that these syndromes are unrelated to tumor size, invasiveness, or metastatic spread 2. They represent immune-mediated or hormone-mediated complications rather than direct tumor effects.
Clinical Significance and Timing
Early recognition is critical because paraneoplastic syndromes are associated with significant morbidity and mortality that can limit effective cancer treatment if undiagnosed 1. The timing relationship with cancer is variable:
- May occur before cancer diagnosis (often the presenting symptom)
- May occur concurrently with cancer diagnosis
- May occur after tumor resection
- May even represent progression from autoimmune disease to paraneoplastic syndrome when occult tumors are later identified 2
Prompt recognition and intervention can limit associated morbidity and mortality, facilitating more effective cancer treatment 1.
Cancer Associations
While virtually any cancer can cause paraneoplastic syndromes, certain malignancies are most frequently implicated 3, 4:
- Small cell lung cancer (SCLC) - most common overall
- Bronchial carcinoid tumors
- Breast and ovarian cancers
- Thymoma
- Gastrointestinal cancers
- Plasma cell tumors
Lung cancers, particularly SCLC, are the most common cancer type associated with paraneoplastic syndromes 5, 6.
Major Categories and Examples
Neurological Paraneoplastic Syndromes
The most extensively characterized category, predominantly associated with SCLC 1, 5:
- Lambert-Eaton myasthenic syndrome (LEMS): Antibodies against voltage-gated calcium channels causing proximal muscle weakness (occurs in 1-1.6% of SCLC)
- Anti-Hu syndrome: Most common paraneoplastic neurological syndrome in lung cancer, causing limbic encephalitis, cerebellar degeneration, sensory neuropathy
- Paraneoplastic cerebellar degeneration
- Opsoclonus-myoclonus
- Encephalomyelitis and sensory neuropathy
- Dermatomyositis: Inflammatory myopathy with characteristic skin findings
Endocrine Paraneoplastic Syndromes
Caused by ectopic hormone production 1, 5:
- Ectopic Cushing syndrome: ACTH production (clinically apparent in 1.6-4.5% of SCLC, biochemical abnormalities in 30-50%)
- SIADH (Syndrome of Inappropriate ADH): Most frequent endocrine syndrome in SCLC, causing hyponatremia
- Carcinoid syndrome: Serotonin production causing flushing, diarrhea, bronchospasm
Other Systems
- Musculocutaneous syndromes
- Hematological syndromes
- Cardiovascular syndromes
- Renal syndromes
Diagnostic Approach
The best way to diagnose a neurological disorder as paraneoplastic is to identify well-characterized anti-onconeural protein antibodies in the patient's serum, which have >90% specificity 4, 7. However, approximately one-third of patients lack detectable antibodies 4.
Key diagnostic principles 1, 8:
- Document target organ inflammation through clinical assessment, laboratory tests, imaging, or biopsy
- Exclude differential diagnoses: metastases, infection, unrelated autoimmune disease
- Test for specific antibodies when high-risk or intermediate-risk syndromes are present
- Screen for underlying cancer guided by antibody profile
Important caveat: Paraneoplastic syndromes can clinically resemble non-neoplastic diseases, making diagnosis challenging and frequently delayed 2.
Treatment Principles
The best way to stabilize paraneoplastic syndromes is to treat the underlying cancer as soon as possible 1, 4. Treatment strategy depends on mechanism:
- Hormonal syndromes: Often improve with tumor resection
- Immunological syndromes: Less predictable response to tumor treatment; may require immunosuppression
Initial immunotherapy options include 9:
- Intravenous methylprednisolone
- Plasma exchange
- Intravenous immunoglobulin (IVIg)
Second-line agents for refractory cases: rituximab, cyclophosphamide, azathioprine, mycophenolate 1
Patients with antibodies against cell surface antigens respond better to immunotherapy than those with intracellular antigen targets 9.
Clinical Management Considerations
Workup for paraneoplastic syndromes should be done in parallel with main cancer diagnosis and staging to minimize delays 1. However, physicians must balance the benefits of treating the paraneoplastic syndrome against potential harms of delaying cancer treatment 1.
The prognosis varies: while some syndromes respond to treatment, many are severely disabling with poor outcomes despite immunosuppression 3, 4. Rapid detection and treatment of the underlying tumor offer the best chance for recovery or prevention of further neurologic deterioration 3.